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ABSTRACT
Asthma is defined as a lung disease characterized by 
airway obstruction and/or narrowing. This condition is 
usually reversible, either spontaneously or with treat-
ment. In addition, an important feature of the disease 
is airway inflammation. Attention to this is a major 
focus of therapy. Somewhat related to the inflam-
matory condition and somewhat to hereditary and 
environmental factors is the feature of airways hyper-
responsiveness. Much of what is currently taught in the 
United States today concerning asthma pathophysiol-
ogy and treatment emanates from guidelines that were 
issued in 1991 and that are currently being revised. 
This guideline initiative has been sponsored by the 
National Heart, Lung and Blood Institute (NHLBI) of 
the National Institutes of Health. As a large and influ-
ential government agency, the NHLBI has provided the 
financial and human resources to distribute important 
information to patients, their families and doctors. 
There are several aspects that should be stressed con-
cerning these guidelines. The importance given to the 
concept of airway inflammation in contrast to the idea 
of simple bronchospasm being the main feature of 
asthma has already been highlighted. Related to this is 
the idea of early intervention with anti-inflammatory 
therapy rather than use of beta-agonist bronchodila-
tors alone. 
 It has been difficult to achieve acceptance of this 
concept by patients and physicians, because chronic 
use of a medication is foreign to many and is also 
costly. A great deal of the time of American asthma 
specialists is devoted to educating their patients on the 
importance of chronic anti-inflammatory therapy. 
Another important focus is the environment. The role 
of the housedust mite, indoor pets, molds and cock-
roaches in increasing airway inflammation in allergic 
asthmatic patients is receiving growing attention. 
Diagnosing the allergic component of the disorder 
with allergy skin tests or RAST and then acting on the 
environment to remove major allergens is now consid-
ered to be of paramount importance. Another impor-
tant aspect of care that has been overlooked in the 
past is the need to monitor pulmonary function with 
some regularity. This should be done at visits to both 
the asthma specialist and family doctor. Some patients 
require daily home monitoring with the use of a peak 
flow meter. Both patients and physicians have failed to 
recognize that significant airway obstruction can occur 
before there are symptoms. Pulmonary function moni-
toring is the only way that this situation can be tracked 
and recognized early in the development of an attack. 
 American physicians are trained to believe that the 
success of their treatment plan depends on communi-
cation with patients and families. They generally rec-
ognize the need to simplify the regimen, to provide 
written information reinforcing their instructions, to 
repeat these at each visit, and to observe the patient 
who uses metered dose inhalers. Many communities in 
the US have support groups for patients and families 
with asthma, which allow people to come together to 
share their concerns and frustrations. This seems to 
enhance compliance with medical therapy, as patients 
feel they are more involved in their disease than if they 
were passive recipients of information. Federal pro-
grams are ongoing to assess the outcome of these 
support interventions.
Key words: anti-inflammatory therapy, asthma, pul-
monary function, support interventions.
DEFINITION OF ASTHMA
Asthma is defined as a lung disease characterized by air-
way obstruction and/or narrowing. This condition is usu-
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ally reversible, either spontaneously or with treatment. In 
addition, an important feature of the disease is airway 
inflammation. Attention to this is a major focus of therapy. 
Somewhat related to the inflammatory condition, and 
somewhat to hereditary and environmental factors, is the 
feature of airway hyperresponsiveness. 
 Much of what is currently taught in the United States 
today concerning asthma pathophysiology and treatment 
emanates from guidelines that were issued by the 
National Institutes of Health in 1991 and which are cur-
rently being revised.1 This guideline initiative has been 
sponsored by the National Heart, Lung and Blood 
Institute (NHLBI) of the National Institutes of Health. As a 
large and influential government agency, the NHLBI has 
provided the financial and human resources to distribute 
important information to patients, their families and 
doctors.
 There are several aspects that should be highlighted 
concerning these guidelines. I have already mentioned 
the importance given to the concept of airway inflamma-
tion in contrast to the idea of simple bronchospasm being 
the main feature of asthma. 
 Related to this is the idea of early intervention with anti-
inflammatory therapy rather than use of beta-agonist 
bronchodilators alone. It has been difficult to achieve 
acceptance of this concept by both patients and physi-
cians, because chronic use of a medication is foreign to 
many and is also costly. Therefore, American asthma spe-
cialists devoted a great deal of time to educating their 
patients on the importance of chronic anti-inflammatory 
therapy.
 Another important focus is the environment. The role of 
the housedust mite, indoor pets, molds and cockroaches 
in increasing airway inflammation in allergic asthmatic 
patients is receiving growing attention. Diagnosing the 
allergic component of the disorder with allergy skin tests 
or radioallergosorbent test (RAST) and then acting on the 
environment to remove major allergens is now consid-
ered to be of paramount importance.
 Another important aspect of care that has been over-
looked in the past is the need to monitor pulmonary func-
tion with some regularity. This should be done at visits to 
both the asthma specialist and family doctor. Some 
patients require daily home monitoring with the use of a 
peak flow meter. Both patients and physicians have failed 
to recognize that significant airway obstruction can occur 
before there are symptoms. Pulmonary function monitor-
ing is the only way that this situation can be tracked and 
recognized early in the development of an attack.
CHARACTERISTICS OF ASTHMA
Asthma is a very prevalent problem in the United States; it 
affects about 1 in 20 Americans. It affects people of all 
ages. An important message regarding its management 
is that it can be controlled but not cured. Even with good 
care, it is somewhat unpredictable. 
 Hospitalization rates for asthma in the US have been 
on the upswing for younger people in particular, and 
deaths from asthma are also increasing. Figure 1 shows 
an alarming increase in deaths since the late 1970s. 2The 
reasons for this are unclear. They include: (i) changes in 
coding, so that patients previously considered to have 
died from wheezy bronchitis are now classified as asth-
matics; (ii) overuse of beta-agonist inhalers; and (iii) lack 
of access to health care or failure to use health care 
resources by indigent people. 
 The upswing in the death rate from asthma is particu-
larly dramatic for the black population.2 This gives cre-
dence to the possibility that poverty, crowding, increased 
allergen exposure in suboptimal housing situations, as 
well as the lack of adequate medical attention, may all be 
factors accounting for this worrisome trend. 
  The cost of asthma in the US is, of course, a prime 
interest. Health care cost control is a major focus in 
American society today. An interesting article by Weiss 
et al. in 1992 showed that a huge segment of asthma 
costs are due to emergency room and hospital inpatient 
care.3 These costs should be able to be reduced through 
the NHLBI guidelines recommendations such as attention 
to the environment, pulmonary function monitoring and 
regular use of anti-inflammatory therapy. 
  Returning to the concept of inflammation, Fig. 2 is a 
schematic representation that explains the concept of the
Fig. 1 Rates of death from asthma in the United States
(1980-91) by race in patients aged 5-34 years. (■) Black,(□)
white, (●) total. (Adapted from Sly. Ann. Allergy 1994; 73:
259-68.)
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Fig. 2 Progression of asthma.
Fig. 3 Early and late phase responses to inhaled allergen 
challenge.
dual phase reaction in asthma. Mast cell mediator 
release results in the rapid onset of bronchoconstriction, 
which reverses fairly easily. Hours later, however, inflam-
matory mediators have encouraged the accumulation of 
inflammatory cells in the airway with resulting narrowing, 
spasm and mucus production. 
 The forced expiratory volume in one second (FEV1) 
reflects this early and late phase reaction (Fig. 3). In the 
clinical situation, this relates to the scenario where a child 
may visit a home with pets and have only brief difficulty 
with breathing. However, later at night the child cannot 
sleep due to escalating asthma and must visit the hospital 
emergency room, possibly requiring hospitalization.
Histology
Histologic sections illustrate the varying degrees of in-
flammation corresponding to asthma severity (Fig. 4). 
Figure 4a shows normal respiratory epithelium, Fig. 4b 
shows some edema and a small amount of inflammatory
Fig. 4 Histologic sections show varying degrees of inflamma-
tion corresponding to asthma severity. (a) Normal respiratory 
epithelium. (b) Some edema and a small amount of inflam-
matory infiltrate, compatible with mild to moderate asthma. 
(c) Inc eased inflammatory infiltrate and some distortion and 
destruction of the epithelium. (d) Total denudation of the epithe-
lium in severe asthma.
infiltrate, compatible with mild to moderate asthma, Fig. 
4c shows increased inflammatory infiltrate and some dis-
tortion and destruction of the epithelium, and Fig. 4d 
shows total denudation of the respiratory epithelium in 
the case of severe asthma.
IMPORTANCE OF PULMONARY FUNCTION 
MONITORING
In regard to the importance of pulmonary function moni-
toring and the failure of patients to appreciate the sever-
ity of their disease, Fig. 5 demonstrates how patients with 
asthma differ from normal subjects in their perception of 
dyspnea.4 Normal subjects who breathe against a resis-
tance so that they have a drop in FEV1 of 25% will com-
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plain of moderate dyspnea (level 3-4 on the Borg scale) 
while patients with asthma will require a 50% drop in 
FEV1 before they complain of dyspnea to that extent. 
 An article by Kikuchi et of. in 19945 shows this same 
failure to appreciate the severity of disease between asth-
matics who have had near fatal asthma episodes when 
compared to normal subjects and to asthma patients who 
have not had severe episodes (Fig. 6). 
 While spirometry is recommended as the best way to 
assess pulmonary function, peak flow determinations are 
preferable to no monitoring. Most primary care physi-
cians do not have access to spirometry, so a strong state-
ment in favor of peak flow determinations has been 
important. Another important message is that peak flow 
monitoring can be done daily at home in order to see 
early signs of deterioration before there is a crisis.
Fig. 5 Perception of dyspnea. (□) Normal subjects (n=27) who
breathe against a resistance so that they have a drop in FEV1 of
25% will complain of dyspnea (level 3-4 on the Borg scale).
(■)Patients with asthma will require a 50% drop before they
complain of dyspnea to that extent (n=18). (Reproduced from
Burdon et al. Am. Rev. Respir. Dis. 1982; 826.)
 Figure 7 shows some of the types of inexpensive peak 
fl w meters that patients can use at home. These are 
available from doctors' offices or from pharmacies. They 
usually cost abouI US$20 and are often available without 
charge, as pharmaceutical firms sometimes provide them 
a a s rvice. 
 A popular way to plot peak flow at home is to use color 
zones that relate to traffic light colors: green for 'go', sig-
naling that everything is stable; yellow for 'caution', sig-
naling the need to pay more attention and use rescue 
beta-agonist medication; and red for 'stop', signaling 
potential danger and the need to call the doctor for 
instructions concerning beta-agonist and possibly steroid 
use. This visual display is helpful for the patients and doc-
tor. R moving variability in the graphic display is a goal of 
therapy.
Fig. 7 Peak flow meters.
Fig. 6 Failure to appreciate the
severity of disease between (▲)
asthma patients who have had near
fatal asthma episodes (n=11) com-
pared to (●) normals (n=12) and
to (■) asthma patients not having
had severe episodes (n=11). Re-
suits are mean±SE (Borg scale)
during breathing at six levels of re-
sistance, (Reproduced from Yoshi-
hiro et al. N. Engl. J. Med. 1994;
330: 1329-34.)
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Fig. 8 Relationship between developing asthma and the level
of housedust mite infestation in the homes of atopic families
(n=20). (□) Wheezing, (■) medication, (■) low peak expiratory
flow rate.
THERAPY
In any discussion of asthma therapy we need to recognize 
the many ways that asthma affects different people. Some 
will suffer episodic upset only; some complain mainly of 
nocturnal difficulties; some are only bothered at certain 
times of year. 
 The causative factors, sometimes called trigger factors, 
are often multiple for the same individual and include 
allergens, infection and irritants. 
 The goals of asthma therapy are to allow a normal life-
style with minimal restriction. Children should be able to 
go to school without missing time and should be able to 
participate in all physical activities. Adults should be able 
to work without absences due to their disease. 
 Therapy should be directed towards decreasing inflam-
mation and restoring normal pulmonary function, prevent-
ing exacerbations and preventing irreversible obstruction. 
Besides aiming at optimizing the lifestyle of patients with 
asthma, eliminating mortality is a major goal.
Non-pharmacologic intervention
Non-pharmacologic intervention is an important aspect 
of therapy in the US. There is a lot of interest in identifying 
allergens and irritants that are causative factors. The 
American public is beginning to be aware of these fac-
tors, though patients and their families are not always 
diligent at following through with important avoidance 
measures. Sporik et al.6 commented on the relationship 
between developing asthma and the level of housedust 
infestation in the homes of atopic families (Fig. 8). There 
was an indirect relationship between the age of first 
wheezing episode and dust mite levels in carpeting.
Fig. 9 Ability of salmeterol to block exercise-induced asthma
for upto 12h. (*) Pre-exercise, (○) placebo, (■) Servent 42μg,
(●) Aibuterol 180μg.
Murray and Ferguson7 showed that the creation of a dust-
free b droom by eliminating carpeting, encasing mat-
tresses and pillows in plastic and removing clutter 
r sulted in fewer asthma symptoms and improved pul-
monary function (Fig. 8). 
 While there is general agreement on the value of elim-
inating allergens in the environment of allergic asthmat-
ics, how to do this in a practical and cost-effective 
manner remains controversial. Most homes have wall-
to-wall carpeting and have only unfinished, low quality 
flooring materials underneath, so that carpet removal 
is oft n impossible. Health insurance plans do not pay 
for acaricides to be used to kill mites in carpeting, nor 
do they pay for mattress and pillow encasing. The hot 
water temperature that is necessary for launderina to be
effective at killing mites (>130°F) is not recommended
by the American Academy of Pediatrics as being safe 
because of concerns about the accidental scalding of 
young children. 
 Unfortunately, these factors taken together mean that 
only the most motivated and affluent families can comply 
with good environmental control measures. The National 
I stitute of Allergy and Infections Disease is currently 
sponsoring a series of studies to determine just how 
important environmental issues are for asthma morbidity 
and mortality so that efforts at environmental control can 
be put in a proper perspective in the future. 
 Pets are another difficult topic for families with an asth-
matic member. It is clear that families often resist elimi-
nating pets even when they definitely induce symptoms. 
The importance of housepets to the American family 
poses a dilemma for the asthma specialist.
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 There is growing interest in US society for the restriction 
of tobacco smoking to limited areas. Most work places 
and all schools prohibit tobacco smoking. Americans are 
inundated by literature attesting to tobacco's role in 
aggravating asthma and in causing cancer and heart 
disease. 
 Air pollutants and irritants appear to affect patients 
with asthma, and their avoidance is another aspect of 
care that is stressed in the US.
Allergen immunotherapy
Allergen immunotherapy is an intervention that is usually 
restricted to patients who have a clearcut allergic compo-
nent to their disease and who cannot avoid the allergens 
that are bothersome to them. Also, it is usually reserved 
for situations where medication use is escalating and 
where pharmacologic therapy has not been easily 
successful. 
 There is less certainty about the role of immunotherapy 
for asthma than for allergic rhinitis. Nevertheless, this 
mode of intervention is sometimes used for allergic asth-
matics. The antigens that are generally injected include 
housedust mite, certain pet allergens, pollens and certain 
molds.
Medications for asthma
The medications that are used in the US for asthma ther-
apy can be grouped into bronchodilators and anti-
inflammatory agents. The bronchodilators include 
beta-agonists, theophylline and anticholinergics. The 
anti-inflammatory agents include the non-steroidal med-
ications (i. e. cromolyn and nedocromil) as well as inhaled 
corticosteroids and oral corticosteroids. 
 It is anticipated that the first oral lipoxygenase inhibitor, 
Zileuton (Abbott Laboratories), will soon be available in 
the US. This will offer a new type of anti-inflammatory 
agent to the American asthma patient. The drug ketotifen 
is not available in the US.
Beta-agonists
A wide variety of short- or intermediate-acting beta-
agonists are available in the US. Albuterol is probably the 
most popular. These agents are available for oral, 
inhaled and parenteral administration. The metered dose 
inhaler is the most popular mode of use. Many changes 
will take place as restrictions on chlorinated hydrocarbon
propellants are increased. Many pharmaceutical firms 
are studying alternative propellants: some moist and 
some dry powder types. 
 Salmeterol is the only long-acting beta-agonist in use 
in the US today. This drug is inhaled from a metered dose 
inhaler. As it provides long-lasting bronchodilation of 
12 h or more, some patients feel enough improve-
ment that they are tempted to give up their anti-inflam-
matory medication. This may result in greater airway 
hyperresponsiveness even though there is adequate 
bronchodilation. 
 There is an emphasis by US physicians that salmeterol 
should not be prescribed unless it is used with an anti-
inflammatory agent. The US Food and Drug Adminis-
tration is carefully monitoring adverse effects with 
salmeterol, because the possibility that overuse of beta-
agonists can cause asthma deaths is an issue. 
 The ability of salmeterol to block exercise-induced 
asthma for up to 12h makes it an attractive therapeutic 
agent, as demonstrated in the report by Kemp et al.8 
(Fig. 9). 
 The question of who should use salmeterol is raised 
because of the possibility that having beta-agonists in the 
system 24 hours a day may actually augment airway 
hyperresponsiveness. Thus, its use is largely limited to 
more severe patients who already use short-acting agents 
repeatedly even though they are on anti-inflammatory 
medications, to patients with repeated exercise periods 
during the day, and to patients with a significant noctur-
nal component to their disease. In the exercise and noc-
turnal asthma patients, salmeterol can be used just in the 
morning (for exercise) or just at night (for sleep).
 Oral beta-agonist use is not popular with US physi-
cians and patients. It is considered that the oral use 
allows too many adverse effects with less bronchodilation 
than a comparable dose by inhalation. 
 When very young children require asthma therapy, a 
compressed air machine with a nebulizer is used to 
administer beta-agonist, often with cromolyn. As this 
device is relatively costly, oral beta-agonist is used for the 
first episodes of wheezing until it is clear that therapy will 
need to be either chronic or intermittent but frequent, 
thereby justifying the cost of the nebulizer system. 
  For patients with severe asthma who continue to 
wheeze even with optimal inhaled beta-agonist therapy, 
in addition to anti-inflammatory therapy, an oral bron-
chodilator such as abuterol tablets is sometimes added 
to the regimen.
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Theophylline
Theophylline was the primary drug for asthma therapy in 
the US during the 1970s and early 1980s. Because 
inflammation is thought to be so important now, and 
because theophylline has only marginal if any anti-
inflammatory activity, this drug has shifted to become one 
of minor importance. Other issues contributing to this 
shift are the need to monitor blood levels to be sure of 
proper dosing, thereby requiring more visits and cost, 
and the relatively high incidence of adverse effects rang-
ing from headaches and irritability to seizures and brain 
damage. 
 Law suits against manufacturers of theophylline prod-
ucts and against physicians who used them were promi-
nent in the media during the late 1980s and early 1990s. 
Toxicity in patients who experienced rapid changes in 
metabolism during febrile illnesses was the cause of mor-
bidity and mortality.
Anticholinergic agents
The anticholinergic agent that is used in asthma care 
in the US today is ipratropium bromide, an analogue 
of atropine but without the unpleasant side-effects such 
as dryness and urinary retention. In chronic asthma, 
ipratropium does not appear to be important, a different 
situation than in chronic obstructive pulmonary disease 
where it is more valuable than a beta-agonist. In acute 
asthma the use of ipratropium with a nebulized beta-
agonist can have additive activity. 
 As anticholinergics are less potent than beta-agonists 
and are not actually approved by the US Food and Drug 
Administration for asthma, they are used infrequently.
Nedocromil and cromolyn
Inhaled nedocromil is a non-steroidal anti-inflammatory 
that appears to block mast cell mediator release and 
decrease bronchial hyperresponsiveness. It is used in the 
US as a chronic maintenance therapy for people with 
mild to moderate asthma. It is often started as a four-
times-a-day therapy and then tapered to twice a day. 
Studies have shown that the addition of nedocromil to 
inhaled steroids can allow the dose of steroids to be 
tapered. 
 Cromolyn has been used in the US for over 20 years. It 
is a non-steroidal anti-inflammatory agent. It also 
appears to block mast cell mediator release and reduce
Table 1. Statistically significant differences favoring 
nedocromil sodium and cromolyn sodium over placebo 
(n=306)
bronchial hyperresponsiveness. Cromolyn has been 
especially valuable for treatment of asthma in young chil-
dren because it is available in ampules to put in a nebu-
lizer as well as in a metered dose inhaler. It is used also in 
older children and in adults with mild to moderate 
asthma. 
  Both cromolyn and nedocromil are used more in the 
US t an in other parts of the world because of the deeply 
eld concern about steroid side-effects that seems to be 
much stronger in the US than in other areas such as 
Europe, Australia and New Zealand. Cromolyn and 
nedocromil are useful just before exercise instead of a 
ta-agonist or as a supplement for beta-agonist med-
ication in addition to their use for chronic asthma. 
 There is controversy about whether the newer prepara-
tion nedocromil offers any advantage over cromolyn. 
Certain studies suggest that nedocromil has a faster onset 
of action, may be more potent against irritant-induced 
asthma and may function better as a twice a day medica-
tion (Table 1).9 Nevertheless, comparative studies show 
the drugs to have a very similar spectrum of activity.
Inhaled corticosteroids
Inhaled corticosteroids are considered to be the optimal 
anti-inflammatory therapy for asthma at this point in time. 
They are often used in children only after a trial with the 
non-steroidal agents because of fears of adverse effects 
on growth and development and not because the non-
steroidals are thought to be of superior efficacy. 
Inhaled corticosteroids are felt to alter arachidonic 
acid metabolism and thus decrease leukotriene produc-
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Fig. 11 Summary of chronic asthma therapy in the USA. 
(Adapted from International Consensus Report. NIH Report No. 
92-3091,1992.)
tion. They are known to decrease the migration and acti-
vation of inflammatory cells such as eosinophils. They 
also appear to upregulate beta receptors. The total effect 
is a decrease in bronchial hyperresponsiveness and air-
way inflammation. 
 Inhaled corticosteroids are to be used chronically as 
'preventers' rather than 'relievers' of asthma. It is difficult 
for some patients to accept this concept, and one of the 
greatest chores for American asthma specialists is to reit-
erate the concept of preventive care over and over again. 
 Figure 1010 presents the possibility that early inter-
vention with inhaled steroid may reduce airway hyper-
responsiveness in a way that cannot be achieved if this
Fig. 10 Early intervention with in-
haled steroids. (Reproduced from 
Haahtela. N. Engl. J. Med. 1994; 
331: 700-5.)
intervention is withheld for 2 or more years. In the study 
by Haahtela et al. patients treated with budesonide 
showed less hyperresponsiveness than those treated with 
terbutaline. After a cross-over from terbutaline to budes-
onide, patients were not able to reach the same improve-
ment as the group that was treated with inhaled steroid 
from the time of diagnosis of asthma. 
 It is difficult for the US primary care physician to recon-
cile the positive information about inhaled steroids with 
articles that point out growth disturbances and weaken-
ing of bone. This again accounts for the greater use of 
cromolyn and nedocromil in the US. 
 The minor adverse effects of inhaled steroid are Can-
dida infection, hoarseness and sore throat. These are 
treatable or reversible on discontinuation of drug. Sys-
temic side-effects are infrequent at usual doses. Never-
theless, the issue of growth suppression has not been 
tot lly laid to rest. 
 The issue of partial immunosuppression is also raised 
t times, as with the possibility of disseminated varicella. 
It is currently recommended by the American Academy of 
Pediatrics that children receiving inhaled corticosteroids 
receive varicella immunization because they may be at 
increased risk of systemic disease. 
 A recent meta-analysis of drug side-effects with beclo-
methasone attested to the lack of negative effect on 
growth. Even high dose use of this agent failed to pro-
duc  growth failure. 
 The inhaled corticosteroids that are available in the US 
today (January 1996) include beclomethasone, triam-
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cinolone and flunisolide. Within the year it is likely that 
fluticasone and budesonide may be approved by the US 
Food and Drug Administration. 
 With inhaled corticosteroids as well as non-steroidal 
anti-inflammatory drugs and beta-agonists, metered 
dose inhaler (MDI) technique is a critical variable. Studies 
have shown that patients repeatedly misuse and unlearn 
proper technique and need to be re-instructed. It is very 
important for doctors and their staff members to spend 
time with patients addressing this issue. The most impor-
tant aspects of proper use include slow inhalation and 
breath-holding for 10s. These steps lead to favorable 
drug deposition in the lung. 
 Spacers and holding chambers are used to further 
augment deposition. Spacers with one-way valves to con-
tain the inhaled medication briefly until it is inhaled are 
called holding chambers. The added space between the 
medication delivery valve and the patient's mouth allows 
for deceleration of the aerosol and evaporation of pro-
pellant so that particles are traveling slower and are 
smaller. This encourages deposition deeper in the lung. 
The valve in these devices allows some delay between 
actuation of the MDI and the inhalation maneuver, which 
is particularly helpful for the young and the elderly, who 
may have difficulty with synchronizing these steps. 
 Very young children (under 5 years) can use inhaled 
steroids by way of an aerochamber with a face mask. 
There is no nebulizer solution of steroid available to 
them.
Oral corticosteroids
Oral corticosteroids are known to be potent anti-asthma 
agents. Their chronic use is associated with a wide range 
of well-known consequences. With this in mind, therapy 
with oral agents is used for short bursts of less than 1 
week to 2 weeks with acute and significant asthma exac-
erbations. Sometimes a brief 'burst' is used to establish a 
patient's best pulmonary function as a reference point for 
following their spirometry and peak flow rates. Acute 
'bursts' are also helpful in distinguishing between rever-
sible disease and fixed obstruction as with chronic 
obstructive pulmonary disease. 
  Prednisone and methylprednisolone are the oral corti-
costeroids that are usually used. These are short-acting 
agents with less potential for affecting the pituitary-
adrenal axis than longer acting agents. 
 Alternate morning oral corticosteroid therapy is used 
as an adjunct to inhaled corticosteroid therapy when
even high-dose inhaled therapy is not adequate for 
ast ma control. In this situation, it is assumed that opti-
mal bronchodilator therapy is also being used. In the 
m st severe cases daily oral therapy may be needed. This 
is giv n in the morning to simulate normal physiology 
corticol secretion and thereby minimize suppression of 
the pituitary-adrenal axis.
CONCLUSIONS
A summary of chronic asthma therapy in the US appears 
on Fig. 11. Patients with very mild disease will be treated 
with as-needed beta-agonist, usually by the inhaled 
rou e. If this therapy is required more than twice per week 
(aside from prophylaxis for exercise-induced asthma), 
then non-steroidal anti-inflammatory therapy will be initi-
at d. Some will choose to go directly to inhaled corticos-
teroid at a low dose at this time. Beta-agonist therapy will 
be used as needed. If beta-agonist drugs are needed 
quite regularly, the dose of inhaled steroid will be 
increased. Also, adjunct medications such as long-acting 
beta-agonist, theophylline and perhaps nedocromil will 
be considered. In the severe situation, all of these may be 
needed, and oral corticosteroid will be added on an 
alternate day basis if possible. As the patient stabilizes 
over time, this therapy can be stepped down in reverse of 
the way it was stepped up during the time of difficulty. 
  American physicians are trained to believe that the suc-
cess of their treatment plan depends on communication 
with patients and families. They generally recognize the 
need to simplify the regimen, to provide written informa-
tion reinforcing their instructions, to repeat these at each 
visit, and to observe the patient who uses metered dose 
inhalers. 
  Many communities have support groups for patients 
and families with asthma. These groups allow people to 
come together to share their concerns and frustration. 
This seems to enhance compliance with medical therapy, 
as patients feel they are more involved in their disease 
than if they were passive recipients of information. 
  Federal programs are ongoing to assess the outcome 
of these support interventions.
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